Intersecting guidelines: Administering erythropoiesis-stimulating agents to chronic kidney disease patients with cancer

Seminars in Dialysis

Volumn 22, Issue 1, 2009, Pages 1-4

  Bennett, Charles L ^a,b,c   Becker, Pamela S ^d   Kraut, Eric H ^e   Samaras, Athena T ^b,c   West, Dennis P ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT;

ANEMIA; ARTICLE; CHRONIC KIDNEY FAILURE; DRUG COMBINATION; HUMAN; NEOPLASM; PRACTICE GUIDELINE; TREATMENT OUTCOME;

ANEMIA; ANTINEOPLASTIC AGENTS; DRUG THERAPY, COMBINATION; HEMATINICS; HUMANS; KIDNEY FAILURE, CHRONIC; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 60349111125     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2008.00524.x     Document Type: Article

References (26)

1. Xue JL, Dalleska F, Murray AM, Collins AJ : Cancer Prevalence in Patients with End-Stage Renal Disease. 2007. Available at http://www.usrds.org/2005/ pres/18U-asn-05-cancer-prevalence-in-pts-with-esrd.pdf, accessed November 5, 2008
2. U.S. Food and Drug Administration : Drugs at FDA. November 2007 Label. Available at http://www.fda.gov/cder/foi/label/2007/103234s5158lbl.pdf, accessed July 11, 2008
3. Morishita E, Masuda S, Nagao M, Yasuda Y, Sasaki R : Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 76 : 105 116, 1997
4. Mori S, Sawada T, Okada T, Kubota K : Erythropoietin and its derivative protect the intestine from severe ischemia/reperfusion injury in the rat. Surgery 143 (4) : 556 565, 2008
5. Nishiya D, Omura T, Shimada K, Matsumoto R, Kusuyama T, Enomoto S, Iwao H, Takeuchi K, Yoshikawa J, Yoshiyama M : Effects of erythropoietin on cardiac remodeling after myocardial infarction. J Pharmacol Sci 101 (1) : 31 39, 2006
6. Weber A, Dzietko M, Berns M, et al. : Neuronal damage after moderate hypoxia and erythropoietin. Neurobiol Dis 20 : 594 600, 2005
7. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, MacDougall IC, Tsakiris D, Burger HU, Scherhag A CREATE Investigators : Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 : 2071 2084, 2006
8. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D CHOIR Investigators : Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 : 2085 2098, 2006
9. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA : The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 : 584 590, 1998
10. Food and Drug Administration Center for Drug Evaluation and Research Joint Meeting of the Cardiovascular and Renal Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee September, 2007. Available at http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4315b1-01-FDA.pdf, accessed July 18, 2007
11. Acs G, Acs P, Beckwith SM, Pitts RL, Clements E, Wong K, Verma A : Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 61 : 3561 3565, 2001
12. Henke M, Laszig R, Rübe C, Schäfer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, Frommhold H : Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362 : 1255 1260, 2003
13. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A, Dodwell D, Baselga J, Biakhov M, Valuckas K, Voznyi E, Liu X, Vercammen E : Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23(25) : 5960 5972, 2005
14. Henke M., Mattern D., Pepe M., Bezay C.,Weissenberger C., Werner M., Pajonk F., Do erythropoietin receptors on cancer cells explain unexpected clinical findings?, Erratum in: J Clin Oncol 2007 Apr 10;25(11):1457
15. New Study Probes Safety of Erythropoiesis-Stimulating Agents. Medscape Medical News, June 10, 2008. Available at http://www.medscape.com/viewarticle/ 575670, accessed July 11, 2008
16. Blau CA, Miller CP, Lowe KA, Mattern D, Valliant-Saunders K, Urban N, Henke M : Predictive testing for erythropoietin induced tumor progression in head and neck cancer. J Clin Oncol 26 : abstr 11007, 2008 CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, Barnato SE, Elverman KM, Courtney DM, McKoy JM, Edwards BJ, Tigue CC, Raisch DW, Yarnold PR, Dorr DA, Kuzel TM, Tallman MS, Trifilio SM, West DP, Lai SY, Henke M : Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299 : 914 924, 2008
17. Glaspy J, Smith R, Aapro M, Ludwig H, Pinter T, Smakal M, Ciuleanu T, Chen L : Results from a Phase III, randomized, double-blind, placebo-controlled study of darbepoetin alfa for the treatment of anemia in patients not receiving chemotherapy or radiotherapy. In : American Association for Cancer Research Annual Meeting Proceedings, April 14-28, 2007, Los Angeles, CA, 2007
18. Oncologic Drugs Advisory Committee : FDA briefing document. May 10, 2007. Continuing Reassessment of the Risks of Erythropoiesis-Stimulating Agents (ESAs) Administered for the Treatment of Anemia Associated with Cancer Chemotherapy. The Food and Drug Administration. 2007. Available at http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4301b2-02-FDA.pdf, accessed July 29, 2008
19. Oncologic Drugs Advisory Committee : FDA Briefing Document. March 13, 2008. Available at http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4345b2- 01-FDA.pdf, accessed April 11, 2008
20. National Comprehensive Cancer Network : NCCN Clinical Practice Guidelines in Oncology: Cancer and Chemotherapy-Induced Anemia. V.1.2009. Available at http://www.nccn.org/professionals/physician-gls/PDF/anemia.pdf, accessed August 7, 2008
21. Press Release : EMEA Recommends a New Warning for Epoetins for their Use in Cancer Patients. June 26, 2008. Available at http://www.emea.europa.eu/pdfs/ human/press/pr/33396308en.pdf, accessed July 11, 2008
22. FDA Complete Response and Labeling Change Order, Epogen. July 30, 2008. Available at http://www.fda.gov/cder/drug/infopage/RHE/epo-procrit/insertEpo. pdf, accessed August 12, 2008
23. FDA Complete Response and Labeling Change Order, Aranesp. July 31, 2008. Available at http://www.fda.gov/cder/drug/infopage/RHE/aranesp/packageinsert. pdf, accessed August 12, 2008
24. Centers for Medicare and Medicaid Studies : Erythropoiesis Stimulating Agents (ESAs) in Cancer and Related Neoplastic Conditions. Issued January 2008, Effective November 2007. Available at http://www.cms.hhs.gov/manuals/downloads/ ncd103c1-Part2.pdf, accessed August 7, 2008
25. Kuenen BC, Rosen L, Smit EF, Parson MR, Levi M, Ruijter R, Huisman H, Kedde MA, Noordhuis P, van der Vijgh WJ, Peters GJ, Cropp GF, Scigalla P, Hoekman K, Pinedo HM, Giaccone G : Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 20 : 1657 1667, 2002
26. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A,Knop S, Joshua D, Sezer O, Ludwig H, Vesole D, Bladé J, Kyle R, Westin J, Weber D, Bringhen S, Niesvizky R, Waage A, von Lilienfeld-Toal M, Lonial S, Morgan GJ, Orlowski RZ, Shimizu K, Anderson KC, Boccadoro M, Durie BG, Sonneveld P, Hussein MA International Myeloma Working Group : Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22 : 414 423, 2008